The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.
 
Claudia A.M. Fulgenzi
No Relationships to Disclose
 
Cian Murphy
No Relationships to Disclose
 
Antonio D'Alessio
No Relationships to Disclose
 
Bernhard Scheiner
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Ipsen
 
Matthias Pinter
Consulting or Advisory Role - Bayer Germany; BMS Norway; Eisai Europe; Ipsen; Lilly; MSD; Roche
Speakers' Bureau - Bayer Germany; BMS GmbH & Co. KG; Eisai; Lilly; MSD; Roche
Travel, Accommodations, Expenses - Bayer; BMSi; Roche
 
Alessio Cortellini
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche
Speakers' Bureau - AstraZeneca; Eisai
 
David J. James Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Mursla Bio; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Da Volterra; Eisai; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley